Gut microbiota has a role in cardiovascular disease and recent findings in rodents show dietary salt can negatively alter gut microbiota composition. High salt intake is a risk factor for cardiovascular disease. Americans consume dietary salt in excess of Dietary Guidelines and American Heart Association recommendations. The objective of this project is to investigate the influence of high dietary salt consumption on the gut microbiota composition in men and women.
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Other
- Masking: Single (Participant)
- Study Primary Completion Date: May 31, 2021
Gut microbiota composition and function has an important role in host physiology. In general, gut microbial diversity is positively correlated with health status. Recent evidence confirms the role of gut dysbiosis in cardiovascular disease. Americans consume 50% more salt than the amount recommended by the Dietary Guidelines and 130% more than recommended by the American Heart Association. Excess salt intake is considered a modifiable risk factor for cardiovascular disease. Changes in the gut microbiota composition followed by immune system activation is reported with high salt intake in animals. In particular, abundance of proinflammatory T helper 17 (Th17) cells increases with excess salt consumption. In contrast, T regulatory (Treg) cells oppose Th17 cell action and may aid in reducing inflammation associated with high salt intake, a hypothesis that has not yet been tested in humans. Only one preliminary study assessed changes in gut bacterial composition with high salt intake in humans, when only men were recruited. The study also found an increase in Th17 cell abundance. Thus, the objective of this study is to investigate the influence of high salt intake on the gut microbiota diversity and Th17 and Treg cell abundance in men and women.
- Other: High Salt
- Consumption of pills containing table salt for 10 days.
- Other: Recommended Salt
- Consumption of pills containing dextrose for 10 days.
Arms, Groups and Cohorts
- Experimental: High Salt
- Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 6,900 mg/d sodium.
- Placebo Comparator: Recommended Salt
- Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with placebo pills.
Clinical Trial Outcome Measures
- Gut microbiota diversity
- Time Frame: On day 10
- The difference in gut microbiota diversity between the two arms.
- T cell profile
- Time Frame: On day 10
- The difference in T regulatory and T helper 17 cells between each arm.
Participating in This Clinical Trial
- normal blood pressure
- cardiovascular disease
- renal disease
- current use of anti-inflammatory agents, glucocorticoids or other immune regulating medications, or certain anti-depressants
- history of intestinal surgery
- inflammatory bowel disease, celiac disease, lactose intolerance, chronic pancreatitis or other malabsorption disorder
- antibiotic use in the past 3 months
- prebiotic, probiotic, or antioxidant supplementation in the past 3 months
- ≥10 lbs weight gain or loss in the past 6 months
- use of tobacco products
- highly trained endurance athletes
- current pregnancy or lactation
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 45 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- University of Delaware
- Provider of Information About this Clinical Study
- Overall Official(s)
- Shannon L Lennon, PhD, RD, Principal Investigator, University of Delaware
- Overall Contact(s)
- Katarina Smiljanec, MS, 5405531230, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.